Top

Cardiovascular Drugs and Therapy

Published in:

01-02-2011 | Letter to the Editor

Phosphatidylcholine-Rich Nanoliposomes: Potential Tools for Serum C-Reactive Protein Reduction?

Author: Amirhossein Sahebkar

Published in: Cardiovascular Drugs and Therapy | Issue 1/2011

Excerpt

To the Editor, …

Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–43.PubMedCrossRef

Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511.PubMedCrossRef

Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension. 2004;44:6–11.PubMedCrossRef

Montecoccu F, Mach F. Therapeutic approaches for reducing c-reactive protein (CRP) levels and the associated cardiovascular risk. Curr Chem Biol. 2009;3:380–4.CrossRef

Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805–12.PubMed

Peng YN, Ho YL, Wu CY, et al. Investigation of C-reactive protein binding to phosphatidyl choline by CZE and ESI-mass analysis. Electrophoresis. 2009;30:1564–71.PubMedCrossRef

Fu T, Borensztajn J. Macrophage uptake of low-density lipoprotein bound to aggregated C-reactive protein: possible mechanism of foam-cell formation in atherosclerotic lesions. Biochem J. 2002;366:195–201.PubMed

Pentikäinen MO, Oörni K, Ala-Korpela M, et al. Modified LDL—trigger of atherosclerosis and inflammation in the arterial intima. J Intern Med. 2000;247:359–70.PubMedCrossRef

Chang MK, Binder CJ, Torzewski M, et al. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA. 2002;99:13043–8.PubMedCrossRef

10.

Mozafari MR. Nanoliposomes: Preparation and Analysis. Methods Mol Biol. 2010;605:29–50.PubMedCrossRef

11.

Maximov VD, Reukov VV, Barry JN, et al. Protein-nanoparticle conjugates as potential therapeutic agents for the treatment of hyperlipidemia. Nanotechnology. 2010;21:265103.PubMedCrossRef

12.

Mackiewicz MR, Hodges HL, Reed SM. C-reactive protein induced rearrangement of phosphatidylcholine on nanoparticle mimics of lipoprotein particles. J Phys Chem B. 2010;114:5556–62.PubMedCrossRef

13.

Liuzzo G, Santamaria M, Biasucci LM, et al. Persistent activation of nuclear factor kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein evidence for a direct proinflammatory effect of azide and lipopolysaccharide-free C-reactive protein on human monocytes via nuclear factor kappa-B activation. J Am Coll Cardiol. 2007;49:185–94.PubMedCrossRef

Title: Phosphatidylcholine-Rich Nanoliposomes: Potential Tools for Serum C-Reactive Protein Reduction?
Author: Amirhossein Sahebkar
Publication date: 01-02-2011
Publisher: Springer US
Published in: Cardiovascular Drugs and Therapy / Issue 1/2011
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-010-6279-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The STEP trials

Springer Medicine

Phosphatidylcholine-Rich Nanoliposomes: Potential Tools for Serum C-Reactive Protein Reduction?

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2011

Long-Term Efficacy of Adding Fenofibric Acid to Moderate-Dose Statin Therapy in Patients with Persistent Elevated Triglycerides

President’s Page

In Memoriam Elliot Rapaport

The Role of β-adrenergic Receptors in the Cardioprotective Effects of Beta-Preconditioning (βPC)

Statins in Heart Failure—Where Do We Stand?

Clinical Trials Update AHA Congress 2010

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page